After four years of follow-up, KEYTRUDA plus LENVIMA reduced the risk of death by 21% versus sunitinib in the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581...
According to the World Health Organization, Acinetobacter species top the list of critical bacterial pathogens that pose the greatest threat to human ...
In the 12-month period ending in December 2022, over 79,000 people in the U.S. were reported to have died of an opioid overdose, of whi...
The Company has been granted permission from the Indian Central Drugs Standard Control Organization (CDSCO) to conduct its global, pivotal Phase 3 clinical...
AIDS Healthcare Foundation (AHF), the world’s largest HIV and AIDS healthcare organization, is seeing a reemergence of monkeypox (now known as mpox) ...
“We are thrilled to partner with BeiGene to help people living with CLL in low- and middle-income countries have access to BRUKINSA,” said Pat ...
The NDA is based on the results of the Phase 3 Clarity AD study and the Phase 2b clinical study, which demonstrated that lecanemab treatment showed a reduc...
During the conference’s poster session, OliX revealed preclinical study results of OLX702A, addressing key mechanisms involved in NASH and obesity. T...
"Hot flashes as a result of menopause can be a serious physical burden on women and impact their quality of life," said Janet Maynard, M.D., M.H.S., direct...
NRC Health has been selected by UCHealth to be its partner in building Human Understanding through personalized healthcare solutions and data-driven i...
The co-development of healthPrecision's Medical Brain artificial intelligence (AI) platform at BayCare will be the first time the technology has been a...
Phase II dose-finding trial met primary endpoint after 46 weeks of treatment, representing an important advancement of Boehringer Ingelheim’s cardi...
Increasing localized access can provide faster results for patients while potentially improving patient outcomes Agreement aims to enable greater access...
Pancreatic adenocarcinoma (PDAC) is one of the most deadly forms of cancer, in part due to the majority of diagnoses being late-stage; the five-year surviv...
© 2025 Biopharma Boardroom. All Rights Reserved.
